BCM
CBAY

Bridgeway Capital Management’s Cymabay Therapeutics CBAY Stock Holding History

Bridgeway Capital Management’s Portfolio CBAY Stock Details CBAY Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q2 		– Sell
-193,500
Closed -$602K – 1396
2022
Q1 		$602K Buy
193,500
+150,000
+345% +$472K 0.01% 894
2021
Q4 		$147K Buy
+43,500
New +$165K ﹤0.01% 1187
2020
Q4 		– Sell
-98,224
Closed -$711K – 1378
2020
Q3 		$711K Sell
98,224
-399,300
-80% -$2.14M 0.02% 779
2020
Q2 		$1.74M Buy
497,524
+342,524
+221% +$988K 0.04% 483
2020
Q1 		$229K Sell
155,000
-122,600
-44% -$206K 0.01% 1017
2019
Q4 		$544K Buy
+277,600
New +$1.04M 0.01% 946

Other funds holding CBAY

ACA
Avoro Capital Advisors New York $10.2B AUM 149.19% 1-Year Est. Return
TCM
TCG Crossover Management Palo Alto, California $3.5B AUM 1,165.83% 1-Year Est. Return
CC
Commodore Capital New York $1.73B AUM 298.96% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
NCM
Nantahala Capital Management New Canaan, Connecticut $2.72B AUM 121.58% 1-Year Est. Return
LCM
Lynx1 Capital Management San Juan, Puerto Rico $633M AUM 173.22% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
DCM
DAFNA Capital Management Los Angeles, California $440M AUM 109.12% 1-Year Est. Return

Bridgeway Capital Management's CBAY Position: Q2 2022 in Review

Bridgeway Capital Management sold out of Cymabay Therapeutics (CBAY) in Q2 2022, closing a stake of 193,500 shares — an estimated $602K sold.

Bridgeway Capital Management first reported a position in CBAY in Q4 2019 and held it in 6 quarters. The position peaked at $1.74M in Q2 2020. 106 funds tracked by Wall St. Rank hold CBAY as of Q2 2022.

  • Bridgeway Capital Management reported no remaining Cymabay Therapeutics position as of Q2 2022 after selling out during the quarter.
  • Bridgeway Capital Management sold 193,500 Cymabay Therapeutics shares in Q2 2022, an estimated $602K.
  • Bridgeway Capital Management first reported a position in Cymabay Therapeutics in Q4 2019 and held it in 6 quarters.
  • Bridgeway Capital Management's Cymabay Therapeutics position peaked at $1.74M in Q2 2020.
  • 106 funds tracked by Wall St. Rank held Cymabay Therapeutics as of Q2 2022.

Based on Bridgeway Capital Management's 13F filing for Q2 2022, filed 15 Aug 2022.